LT3159409T - Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui - Google Patents

Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui

Info

Publication number
LT3159409T
LT3159409T LTEP15810097.4T LT15810097T LT3159409T LT 3159409 T LT3159409 T LT 3159409T LT 15810097 T LT15810097 T LT 15810097T LT 3159409 T LT3159409 T LT 3159409T
Authority
LT
Lithuania
Prior art keywords
duschenal
antiprasmic
treatment
nucleic acid
distrophy
Prior art date
Application number
LTEP15810097.4T
Other languages
English (en)
Inventor
Naoki Watanabe
Yuuichirou TONE
Shin`ichi TAKEDA
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co., Ltd.
National Center Of Neurology And Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co., Ltd., National Center Of Neurology And Psychiatry filed Critical Nippon Shinyaku Co., Ltd.
Publication of LT3159409T publication Critical patent/LT3159409T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
LTEP15810097.4T 2014-06-17 2015-06-16 Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui LT3159409T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014124157 2014-06-17
PCT/JP2015/067238 WO2015194520A1 (ja) 2014-06-17 2015-06-16 アンチセンス核酸

Publications (1)

Publication Number Publication Date
LT3159409T true LT3159409T (lt) 2020-01-27

Family

ID=54935505

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15810097.4T LT3159409T (lt) 2014-06-17 2015-06-16 Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui

Country Status (30)

Country Link
US (4) US9840706B2 (lt)
EP (3) EP3159409B1 (lt)
JP (6) JP6208349B2 (lt)
KR (1) KR102335810B1 (lt)
CN (2) CN106661577B (lt)
AU (3) AU2015277924B2 (lt)
BR (2) BR112016029369B1 (lt)
CA (1) CA2951221A1 (lt)
CO (1) CO2017000357A2 (lt)
CY (1) CY1122462T1 (lt)
DK (1) DK3159409T3 (lt)
ES (2) ES2765463T3 (lt)
HR (1) HRP20200042T1 (lt)
HU (1) HUE047502T2 (lt)
IL (1) IL249574B (lt)
LT (1) LT3159409T (lt)
MX (2) MX373052B (lt)
MY (2) MY202674A (lt)
PH (1) PH12016502501A1 (lt)
PL (2) PL3159409T3 (lt)
PT (1) PT3159409T (lt)
RS (1) RS59764B1 (lt)
RU (1) RU2695430C2 (lt)
SG (2) SG10201912858VA (lt)
SI (1) SI3159409T1 (lt)
SM (1) SMT202000006T1 (lt)
TW (2) TWI721461B (lt)
UA (1) UA121117C2 (lt)
WO (1) WO2015194520A1 (lt)
ZA (1) ZA201700142B (lt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015194520A1 (ja) * 2014-06-17 2015-12-23 日本新薬株式会社 アンチセンス核酸
CN113913426B (zh) 2015-09-15 2024-08-02 日本新药株式会社 反义核酸
JP6875684B2 (ja) * 2015-09-16 2021-05-26 日本新薬株式会社 筋萎縮症治療用アンチセンス核酸
SG10201912902TA (en) 2015-10-09 2020-02-27 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
US20190262375A1 (en) 2016-06-30 2019-08-29 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
KR102646318B1 (ko) 2016-12-19 2024-03-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
HRP20240705T1 (hr) 2016-12-19 2024-08-30 Sarepta Therapeutics, Inc. Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020537497A (ja) * 2017-09-22 2020-12-24 アビディティー バイオサイエンシーズ，インク． エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3874044A1 (en) * 2018-11-02 2021-09-08 BioMarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
EP3959319A4 (en) 2019-04-25 2023-06-07 Avidity Biosciences, Inc. NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING
US20220282247A1 (en) * 2019-08-02 2022-09-08 Research Institute At Nationwide Children's Hospital Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies
PE20230237A1 (es) * 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
IL307937A (en) 2021-04-30 2023-12-01 Sarepta Therapeutics Inc Treatment methods for muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
CA3229962A1 (en) 2021-08-24 2023-03-02 Peptidream Inc. Human transferrin receptor-binding antibody-peptide conjugate
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
AU2022424485A1 (en) 2021-12-27 2024-07-11 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
JP2025509438A (ja) 2022-03-17 2025-04-11 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミデートモルホリノオリゴマーコンジュゲート
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
WO2025174995A1 (en) * 2024-02-13 2025-08-21 Keros Therapeutics, Inc. Methods of using activin a and myostatin signaling inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033986T2 (de) 1989-12-20 2003-03-13 Antivirals Inc., Portland Ungeladene, auf Morpholin basierende Polymere mit Chiralen, Phosphor enthaltenden Brücken zwischen den Untereinheiten
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP2530155B1 (en) 2002-11-25 2016-03-16 Masafumi Matsuo ENA nucleic acid drugs modifying splicing in mRNA precursor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
SI2206781T1 (sl) 2004-06-28 2016-05-31 The University Of Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP5143450B2 (ja) * 2007-03-14 2013-02-13 斉 大戸 Ｈｌａ−ｂローカスにおける新規アリル
DK2203173T3 (en) * 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
CA2884340C (en) 2007-11-15 2017-07-25 Sarepta Therapeutics, Inc. Method of synthesis of morpholino oligomers
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
EP2762567B1 (en) * 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Multiple exon skipping compositions for DMD
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
EP2672977A1 (en) * 2011-02-08 2013-12-18 The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System Antisense oligonucleotides
CN108611349A (zh) 2011-12-28 2018-10-02 日本新药株式会社 反义核酸
ES2907250T3 (es) 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
AU2013285698A1 (en) 2012-07-03 2015-02-19 Biomarin Technologies B.V. Oligonucleotide for the treatment of muscular dystrophy patients
JP2014124157A (ja) 2012-12-27 2014-07-07 Nihon Cornstarch Corp コーヒー飲料
RU2702424C2 (ru) 2014-03-12 2019-10-08 Ниппон Синяку Ко., Лтд. Антисмысловые нуклеиновые кислоты
WO2015194520A1 (ja) * 2014-06-17 2015-12-23 日本新薬株式会社 アンチセンス核酸

Also Published As

Publication number Publication date
TW201625274A (zh) 2016-07-16
US20180044675A1 (en) 2018-02-15
SG11201610130VA (en) 2017-01-27
JP7041879B2 (ja) 2022-03-25
HUE047502T2 (hu) 2020-04-28
CN106661577B (zh) 2020-05-12
RS59764B1 (sr) 2020-02-28
EP3660154B1 (en) 2025-04-16
AU2024201290A1 (en) 2024-03-21
UA121117C2 (uk) 2020-04-10
CO2017000357A2 (es) 2017-06-09
PH12016502501A1 (en) 2017-03-22
PL3660154T3 (pl) 2025-07-28
EP3159409A4 (en) 2018-01-10
JP2026010142A (ja) 2026-01-21
US9840706B2 (en) 2017-12-12
MY194170A (en) 2022-11-16
BR112016029369B1 (pt) 2020-12-08
RU2695430C2 (ru) 2019-07-23
JP2020182459A (ja) 2020-11-12
WO2015194520A1 (ja) 2015-12-23
TWI721461B (zh) 2021-03-11
JPWO2015194520A1 (ja) 2017-04-20
TWI666317B (zh) 2019-07-21
SI3159409T1 (sl) 2020-02-28
MX373052B (es) 2020-05-11
US20170204410A1 (en) 2017-07-20
NZ728103A (en) 2021-11-26
ES2765463T3 (es) 2020-06-09
JP2022082539A (ja) 2022-06-02
PL3159409T3 (pl) 2020-05-18
MX420315B (es) 2025-02-10
US20220049257A1 (en) 2022-02-17
EP3660154A1 (en) 2020-06-03
JP6701139B2 (ja) 2020-05-27
HRP20200042T1 (hr) 2020-03-20
RU2017101172A3 (lt) 2018-12-24
RU2017101172A (ru) 2018-07-17
IL249574A0 (en) 2017-02-28
CN106661577A (zh) 2017-05-10
EP4596047A3 (en) 2025-10-22
AU2015277924B2 (en) 2021-02-25
AU2015277924A1 (en) 2017-02-02
ES3027057T3 (en) 2025-06-12
US12060556B2 (en) 2024-08-13
RU2019121781A (ru) 2019-07-22
TW201936922A (zh) 2019-09-16
MX2016016526A (es) 2017-04-04
KR20170017939A (ko) 2017-02-15
NZ765451A (en) 2024-04-26
SMT202000006T1 (it) 2020-03-13
EP3660154C0 (en) 2025-04-16
SG10201912858VA (en) 2020-02-27
ZA201700142B (en) 2020-05-27
JP2018027087A (ja) 2018-02-22
JP2024023899A (ja) 2024-02-21
EP4596047A2 (en) 2025-08-06
DK3159409T3 (da) 2020-01-27
CN111575282B (zh) 2024-05-14
BR112016029369A2 (pt) 2018-01-09
CY1122462T1 (el) 2021-01-27
IL249574B (en) 2021-02-28
EP3159409A1 (en) 2017-04-26
CN111575282A (zh) 2020-08-25
MX2020004417A (es) 2020-08-06
PT3159409T (pt) 2020-01-21
US20250084412A1 (en) 2025-03-13
BR122020020864B1 (pt) 2022-06-21
JP6208349B2 (ja) 2017-10-04
EP3159409B1 (en) 2019-12-04
AU2021203383A1 (en) 2021-06-24
CA2951221A1 (en) 2015-12-23
MY202674A (en) 2024-05-14
US11193125B2 (en) 2021-12-07
KR102335810B1 (ko) 2021-12-03
AU2021203383B2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
LT3159409T (lt) Antiprasminė nukleorūgštis, skirta panaudoti diušeno raumenų distrofijos gydymui
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
LT3334422T (lt) Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
PL3118311T3 (pl) Antysensowny kwas nukleinowy
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
SI3105328T1 (sl) Multiplo genomsko inženirstvo omogočeno s CRISPR
EP3842103C0 (en) ADJUSTABLE DUMBBELL SYSTEM
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
HUE059158T2 (hu) Eljárás pridopidin elõállítására
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
EP3286549A4 (en) BIOSENSOR
DK3231444T3 (da) Ny behandling
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
DK3094731T3 (da) Saccharidmodificerede nukleinsyremolekyler
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
EP3156789C0 (en) BIOSENSOR
DK3215607T3 (da) Phagterapi
DK3204335T3 (da) Elektrokoagulation reaktor
IL256206A (en) Mct4 inhibitors for treating disease
BR112016022976A2 (pt) Métodos para o tratamento de hcv
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
LT3294769T (lt) Daugybinei mielomai (dm) skirtas gydymas
LT3191514T (lt) Ligandai, sustiprinantys gonadotropinų biologinį aktyvumą